Kuros Biosciences AG (SWX:KURN)
22.82
+0.32 (1.42%)
Aug 4, 2026, 2:12 PM CET
Kuros Biosciences AG Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 19.77 | 19.76 | 16.89 | 26.03 | 31.4 |
Cash & Short-Term Investments | 19.77 | 19.76 | 16.89 | 26.03 | 31.4 |
Cash Growth | 0.03% | 16.98% | -35.09% | -17.09% | -0.66% |
Accounts Receivable | 30.21 | 14.69 | 7.62 | 3.05 | 1.85 |
Other Receivables | 9.98 | 3.01 | 1.43 | 0.87 | 0.39 |
Total Trade Receivables | 40.2 | 17.7 | 9.06 | 3.91 | 2.25 |
Inventory | 21.35 | 10.36 | 5.77 | 3.43 | 1.93 |
Other Current Assets | 1.35 | 1.26 | 0.61 | 0.58 | 0.51 |
Total Current Assets | 82.67 | 49.08 | 32.34 | 33.96 | 36.08 |
Net Property, Plant & Equipment | 4.68 | 3.32 | 3.14 | 2.51 | 2.68 |
Other Intangible Assets | 16.59 | 16.44 | 19.63 | 21 | 24.8 |
Goodwill | 24.3 | 21.31 | 29.1 | 31.71 | 36.62 |
Other Long-Term Assets | 5.64 | 2.56 | 0.77 | 0.55 | - |
Total Assets | 133.88 | 92.7 | 84.98 | 89.72 | 100.18 |
Accounts Payable | 13.81 | 7.58 | 1.55 | 1.41 | 0.93 |
Accrued Expenses | 27.18 | 14.76 | 9.43 | 5.36 | 3.76 |
Current Portion of Leases | 0.65 | 0.58 | 0.69 | 0.45 | 0.35 |
Other Current Liabilities | 0.5 | - | - | 6.4 | 7.35 |
Total Current Liabilities | 42.14 | 22.92 | 11.67 | 13.62 | 12.38 |
Long-Term Leases | 0.74 | 1.39 | 1.86 | 1.62 | 2.01 |
Other Long-Term Liabilities | 6.52 | 3.98 | 4.01 | - | 1.36 |
Total Long-Term Liabilities | 7.25 | 5.36 | 5.87 | 1.62 | 3.37 |
Total Liabilities | 49.39 | 28.28 | 17.54 | 15.24 | 15.75 |
Common Stock | 3.23 | 3.07 | 4.37 | 3.95 | 3.6 |
Treasury Stock | - | - | -0.02 | -0.02 | -0.02 |
Additional Paid-in Capital | 66.87 | 64.84 | 87.18 | 173.23 | 169.56 |
Accumulated Other Comprehensive Income | 31.76 | 27.56 | 26.44 | 23.06 | 22.25 |
Retained Earnings | -17.38 | -31.05 | -50.53 | -125.74 | -110.96 |
Shareholders' Equity | 84.48 | 64.42 | 67.43 | 74.48 | 84.43 |
Total Liabilities & Equity | 133.88 | 92.7 | 84.98 | 89.72 | 100.18 |
Total Debt | 1.39 | 1.97 | 2.55 | 2.07 | 2.35 |
Net Cash (Debt) | 18.38 | 17.8 | 14.35 | 23.96 | 29.04 |
Net Cash Growth | 3.28% | 24.05% | -40.13% | -17.50% | 0.15% |
Net Cash Per Share | 0.44 | 0.48 | 0.39 | 0.71 | 0.89 |
Book Value | 84.48 | 64.42 | 67.43 | 74.48 | 84.43 |
Book Value Per Share | 2.04 | 1.73 | 1.84 | 2.20 | 2.57 |
Tangible Book Value | 43.59 | 26.67 | 18.71 | 21.78 | 23.01 |
Tangible Book Value Per Share | 1.05 | 0.72 | 0.51 | 0.64 | 0.70 |